Blog
Fifty years of Dupuytren’s Patients Reviewed
One of the more puzzling things about Dupuytren’s is the variation in demographic data. Taking away the variation in results from different surgeons doing different operations, one would expect a standard pattern of who is at risk, what conditions are associated. Not so. A review of nearly 3000 Dupuytren patients
Management strategies for Dupuytren’s
The management options for people with Dupuytren’s can appear as confusing as the biology. This review provides a nice overview of Dupuytren’s disease and a practical decision tree approach to manage hands affected by Dupuytren’s. It’s worth a read: https://dupuytrens.org/DupPDFs/2006_Bayat_1586.pdf
Homeopathy for Dupuytren’s
HH Reckeweg (1905-1985) in Germany developed the Disease Evolution Table of homeopathic medicine. In this system, Dupuytren’s contracture is classified as a mesenchymal-connective tissue cellular-degeneration phase disease. This should be the starting point for homeopathic physicians to begin developing a homeopathic cure for Dupuytren’s. See where Dupuytren’s fits on the
Machines to Stretch Dupuytren’s Cords
There is not yet a perfect solution for PIP contractures from Dupuytren’s Disease, or for PIP contractures in general. One approach has been to use temporary skeletal fixation devices to slowly lengthen Dupuytren’s cords and scar tissue. The collagen bundles in Dupuytren’s cords don’t actually stretch: they remodel, disconnecting crosslinks
Tissue markers for Dupuytren’s
Is it possible to predict the course of Dupuytren’s in an individual? Who will need surgery? Who will have rapid progression or an early recurrence after surgery and who won’t? Family and personal history provide general trends, but that’s all. Several studies have correlated the cellularity of nodule tissue and
Dupuytren’s, epilepsy, barbiturates and genes: a chemical love …triangle.
Dupuytren’s has been associated with epilepsy. The type or cause of epilepsy doesn’t seem to matter. What does matter is the specific medication phenobarbitone. Dupuytren’s was not common in epileptics prior to the common use of this medicine, but is very common in people on long term treatment with it:
Treatment effectiveness for Dupuytren’s needs documentation
Progress into new territory requires an open mind: beware conformity; examine failure; engage outsiders, and be aware of undocumented claims. This interesting report of an injection treatment for Dupuytren’s would be worth considering if published in an independent peer reviewed format rather than on the manufacturer’s web site: https://www.dupuytrens.org/DupPDFs/2001_Beller.pdf
Rock Climbing and Dupuytren’s – an interesting analysis
Dupuytren’s is an inherited systemic disorder of either the threshold or the feedback inhibition of the biology of scar formation, contracture and maturation. It is not spontaneous, but triggered in specific areas having the common characteristic of being subjected to repeated high shearing or stretching forces: palmar fascia, plantar fascia,
How the FDA sees Collagenase for Dupuytren’s
Why is it taking so long for collagenase injection treatment to be available to treat Dupuytren’s? Trials have been ongoing for over 10 years. The answer: collagenase is an extremely potent substance, and the FDA has required very detailed proof not only that it works, but that it is safe,
Recent Dupuytren Publications
- The Evidence for Perioperative Anesthetic Techniques in the Prevention of New-Onset or Recurrent Complex Regional Pain Syndrome in Hand Surgery
- Palmar Fibromatosis, Updated Review With Relationship to the A1 Pulley, Trigger Finger, and Presence of the Sonographic Comb Sign
- Treatment utilization for Dupuytren's contracture in the United States is influenced by socioeconomic factors
- Impact of Collagenase Injection on Dupuytren Disease Treatment in Japan: A Comprehensive Survey of Trends
- Ledderhose's Disease